Purchase Order 75D30121P11147
- Not listed
- This is a $169,504.71 firm-fixed price purchase order awarded by the U.S. Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to Certara USA Inc., doing business as Tripos (DE), a technology-enabled drug development and drug safety consultancy. The contract provides annual named user server licenses for Certara's Phoenix WinNonlin, Phoenix Connect, Phoenix NLME software, as well as an unlimited server license for distributed computing. This supports the FDA's...
- This is a definitive, firm-fixed-price contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to Certara USA Inc., a for-profit technology-enabled drug development and drug safety consultancy. The $748,500.00 contract is for services to strengthen death reporting and surveillance, with a completion date of September 29, 2019. The contract does not have a set-aside designation. Certara USA Inc. has previously provided software...
- This firm-fixed price purchase order contract was awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to Certara UK LIMITED, doing business as Certara, a for-profit limited liability company. The $164,400 contract provides annual licenses and maintenance support for Certara's SIMCYP physiologically-based pharmacokinetic modeling software. The software is used by the FDA's Office of Clinical Pharmacology to review submissions from pharmaceutical sponsors,...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Pharsight Corporation, a subsidiary of Certara USA Inc. The contract, valued at $153,470.00, is for the provision of the "PHOENIX QUANTUM SOFTWARE BUNDLE" and is a total small business set-aside. The contract has a completion date of July 21, 2017. Certara USA Inc. is a leading global technology-enabled drug development and drug safety consultancy, specializing in biosimulation...
- The U.S. Food and Drug Administration (FDA) awarded a firm fixed price purchase order to Certara UK Limited, doing business as Certara, a for-profit limited liability company, for SIMCYP software licenses and maintenance support. The $114,316.00 contract will allow the FDA's Office of Clinical Pharmacology Drug Reviewers to complete their review of investigational new drugs. Certara has previously provided this physiologically-based pharmacokinetic modeling software to the FDA and...
- The Department of Health and Human Services, Food and Drug Administration awarded a fixed-price purchase order contract to Certara USA Inc., doing business as Tripos (De), for an annual Phoenix Quantum software subscription. The contract, with a potential value of $216,547.78, provides the FDA's Office of Clinical Pharmacology with the necessary modeling and simulation tools to analyze and verify sponsor submissions, including Investigational New Drug, New Drug, Biologics Licensing, and...
- The federal contract award, valued at $10,743.00, was issued by the National Cancer Institute (NCI) to Certara USA Inc., a leading global technology-enabled drug development and drug safety consultancy, for the procurement of software licenses. The contract is a firm-fixed price purchase order with no set-aside designation and an ultimate completion date of August 13, 2025. Certara USA Inc. has received numerous prime contract awards from the NCI, Food and Drug Administration (FDA), and National...
- This is a firm-fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Simulations Plus Inc. for an annual software license for one user to access the company's ADMET and GastroPlus modeling and simulation software. The total ceiling value of the contract is $96,898.01 and the ultimate completion date is January 31, 2026. The software provided under this award supports pharmaceutical drug research, development, and regulatory assessment through...
- The Department of Health and Human Services' National Institutes of Health has awarded a firm fixed-price purchase order to Certara USA Inc., a leading global drug development and drug safety consultancy, for the provision of Phoenix WinNonlin software licenses. The $12,266.00 contract will enable federal scientists and reviewers to conduct clinical pharmacology, pharmacometric, and regulatory review analyses on data submitted by industry sponsors. Certara has received numerous prime contracts...
- The Food and Drug Administration awarded a firm fixed-price purchase order to Certara UK LIMITED (doing business as Certara) on September 6, 2023, for SIMCYP software licenses with a ceiling value of $815,948. The contract will be performed in Great Britain, United Kingdom, and is scheduled for ultimate completion by September 20, 2028. No set-aside designation was applied to this award. Certara provides physiologically-based pharmacokinetic (PBPK) modeling software that simulates drug...
This federal contract award, valued at $45,776, was made by the Centers for Disease Control and Prevention (CDC) to Certara USA Inc., doing business as Tripos (De). The contract provides for the licensing and implementation of Certara's Phoenix software for pharmacokinetic and pharmacodynamic modeling and simulation to support the CDC's public health decision-making. Certara is a technology-enabled drug development and drug safety consultancy that specializes in accelerating medicines to patients through the use of biosimulation, technology, and services. This contract does not have a set-aside designation, and the ultimate completion date is September 10, 2024. Certara has a history of providing similar modeling and simulation software and services to other Department of Health and Human Services agencies, including the Food and Drug Administration (over $500,000 in awards) and the National Institutes of Health (over $25,000 in awards).
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Exercise an Option | $15.9k | 5/11/23 | |
| P00001 | Exercise an Option | $15.2k | 3/23/22 | |
| Not listed | Not listed | $14.7k | 5/27/21 |